LYKALABSNSELyka Labs Limited· PharmaceuticalsMediumNeutral
Announced Thu, 9 Apr · 16:49 IST

Lyka Labs Limited has informed the Exchange about General Updates

Nclt Scheme FiledStrategic Transactions View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹58.10
prior close
₹59.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1-2.7-0.2-0.5-0.3-2.1-0.7+3.2-0.1+2.4-1.0+10.2+23.9+23.5
Up moveDown movePending
AI summary

Lyka Labs Limited has informed the stock exchanges that its Scheme of Amalgamation with Lyka Exports Limited (the transferor company) has become effective from 8th April, 2026, after the certified copy of the NCLT Ahmedabad Bench order (dated 16th March, 2026) was filed with the Registrar of Companies, Ahmedabad. The scheme merges Lyka Exports into Lyka Labs with a retrospective appointed date of 1st April, 2022. As a result, Lyka Labs' authorised share capital has automatically increased to Rs. 59 crore, comprising 5.7 crore equity shares of Rs. 10 each and 2 lakh redeemable preference shares of Rs. 100 each. The move consolidates the group structure under a single listed entity.

Likely market impact

Shareholders should note that the amalgamation is now legally effective, which typically means the transferor company's business and assets are absorbed into Lyka Labs, potentially leading to changes in shareholding pattern or share swap ratio as per the scheme. Investors should await the next filing for the share exchange/allotment details and record date for any entitlement.